Why choose Invokana (canagliflozin) - After first line, take a firm line
Invokana Cardiovascular Icon

Cardiovascular

Reduce the long-term risk of CV events with Invokana

  • CANVAS showed a 14% relative risk reduction for major adverse cardiovascular events among a mix of both primary and secondary prevention patients HR, 0.86 (95% CI, 0.75-0.97). ARR: 4.6 fewer MACE events per 1000 patient-years. 1
Reduce the long-term risk of CV events with Invokana - Invokana (canagliflozin) Chart

Adapted from Neal B et al 2017 1

  • Among the secondary prevention cohort of patients, CANVAS showed an 18% relative risk reduction for major adverse cardiovascular events HR, 0.82 (95% CI, 0.72-0.95). ARR: 7.2 fewer MACE events per 1000 patient-years.1

Invokana consistently reduced the risk of hospitalisation due to heart failure

Invokana consistently reduced the risk of hospitalisation due to heart failure - Invokana (canagliflozin) Chart

Adapted from Neal B et al 2017 1

  • CANVAS showed a 33% reduction in risk of hospitalisation due to heart failure among a mix of both primary and secondary prevention patients HR, 0.67 (95% CI, 0.52-0.87). ARR: 3.2 fewer hospitalisations due to heart failure per 1000 patient-years. 1
Invokana Renal Outcomes Icon

Renal Outcomes

Improved renal outcomes are an additional benefit of Invokana and not a licensed indication.
Invokana should not be initiated or the dose increased in patients with an eGFR of <60ml/min/1.73m 3. Invokana dose should be adjusted to or maintained at 100mg in patients who develop renal impairment (eGFR 45 – 60ml/min/1.73m 3) while on treatment. If renal function falls persistently below 45ml/min/1.73m 3, treatment with Invokana should be discontinued.

Invokana is associated with a 47% risk reduction in time to first nephropathy event*

HR, 0.53 (95% CI, 0.33–0.84). ARR: 1.3 fewer nephropathy events per 1000 patient-years 2

Invokana is associated with a 47% risk reduction in time to first nephropathy event* HR, 0.53 (95% CI, 0.67 – 0.79) - Invokana (canagliflozin) Chart

Adapted from Perkovic V, et al. 2018. SOC: standard of care

* First adjudicated nephropathy event included doubling of serum creatinine, end-stage renal disease, or renal death.

Stabilise eGFR levels for the long term

  • With usual standard of care, eGFR declines over time.
  • After an initial fall in mean eGFR during the first 4 weeks of treatment, Invokana stabilises eGFR levels over 6.5 years. 2
Stabilise eGFR levels for the long term - Invokana (canagliflozin) Chart

Adapted from Perkovic V, et al. 2018. SOC: standard of care

Offer additional renal benefits to your patients:

Compared with standard of care:

  • 27% reduction in the progression of albuminuria HR, 0.73 (95% CI, 0.67-0.79). ARR: 39.3 fewer instances of albuminuria progression per1000 patient-years. 2,3
  • 70% increase in albuminuria regression,  HR, 1.70 (95% CI, 1.51 – 1.91). Absolute benefit: 105.9 more instances of albuminura regression per 1000 patient-years. 4

Offer additional renal benefits to your patients - Invokana (canagliflozin) Chart

Adapted from Fulcher G, et al. EASD 2017. Intent-to-treat analysis. SOC: standard of care

References
  1. Neal B, et al. N Engl J Med 2017;377(7):644-57
  2. Perkovic V, et al. Lancet Diabetes Endocrinol 2018;6(9):691-704
  3. Reference 1(6)
  4. Fulcher G, et al. The CANVAS Program (CANagliflozin cardioVascular Assessment Stud). Presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD); 2017 Sep 15; Lisbon, Portugal

Date of preparation: March 2019 | Job code: UK/INV-18087a